4-乙基-N-甲氧基-N-甲基苯甲酰胺 | 1024606-29-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-乙基-N-甲氧基-N-甲基苯甲酰胺
• 英文名称: 4-ethyl-N-methoxy-N-methylbenzamide
• CAS: 1024606-29-8
• 化学式: C₁₁H₁₅NO₂
• mdl: MFCD14707534
• 分子量: 193.246
• InChiKey: CRNLPUXYSGDQPU-UHFFFAOYSA-N

物化性质

• 沸点：
  329.4±21.0 °C(Predicted)
• 密度：
  1.050±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-乙基-N-甲氧基-N-甲基苯甲酰胺 在 [ruthenium(II)(η⁶-1-methyl-4-isopropyl-benzene)(chloride)(μ-chloride)]₂ 、 碘苯二乙酸 、 三氟乙酸 、 三氟乙酸酐 作用下， 反应 16.0h， 以78%的产率得到4-ethyl-2-hydroxy-N-methoxy-N-methylbenzamide
  参考文献：
  名称：

  芳基Weinreb酰胺上钌催化的CH氧化

  摘要：

  多功能的钌催化剂可在极温和的反应条件下，使芳基Weinreb酰胺进行空前的CH键加氢键氧化，从而获得了有价值的邻羟基化醛。机理研究为动力学相关的CH键活化提供了有力的支持。

  DOI：

  10.1021/ol303520h

文献信息

• Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase
  申请人：YALE UNIVERSITY

  公开号：US20140356322A1

  公开（公告）日：2014-12-04

  The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins that are degraded and/or otherwise inhibited by bifunctional compounds of the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand that binds to the ubiquitin ligase and on the other end a moiety that binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds of the present invention, consistent with the degradation/inhibition of targeted polypeptides.

  本发明涉及双功能化合物，其作为靶向泛素化的调节剂具有实用性，特别是作为本发明的双功能化合物对各种被降解和/或受到抑制的多肽和其他蛋白质的抑制剂。具体而言，本发明涉及含有一端结合泛素连接酶的VHL配体，另一端结合靶蛋白的基团的化合物，使得靶蛋白靠近泛素连接酶以促使该蛋白的降解（和抑制）。本发明展示了与本发明化合物相关的广泛的药理活性范围，与靶向多肽的降解/抑制一致。
• Heterobicyclic thiophene compounds and methods of use
  申请人：Blake F. James

  公开号：US20070197537A1

  公开（公告）日：2007-08-23

  Compounds of Formula I and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula I and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  公式I的化合物及其药用盐可用于抑制受体酪氨酸激酶，并用于治疗由此介导的疾病。公开了使用公式I的化合物及其药用盐的方法，用于体外、原位和体内诊断、预防或治疗哺乳动物细胞中的这类疾病，或相关的病理情况。
• Ruthenium-Catalyzed C–H Oxygenation on Aryl Weinreb Amides
  作者：Fanzhi Yang、Lutz Ackermann

  DOI：10.1021/ol303520h

  日期：2013.2.1

  Versatile ruthenium catalysts enabled unprecedented C–H bond oxygenations of aryl Weinreb amides with ample scope under exceedingly mild reaction conditions, thereby also giving access to valuable ortho-hydroxylated aldehydes. Mechanistic studies provided strong support for a kinetically relevant C–H bond activation.

  多功能的钌催化剂可在极温和的反应条件下，使芳基Weinreb酰胺进行空前的CH键加氢键氧化，从而获得了有价值的邻羟基化醛。机理研究为动力学相关的CH键活化提供了有力的支持。
• ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS
  申请人：Parker F. Michael

  公开号：US20080085894A1

  公开（公告）日：2008-04-10

  There is provided a series of novel α-(N-sulfonamido)acetamide compounds of the Formula (I) wherein R, R 1 , R 2 and R 3 are defined herein, which are inhibitors of β-amyloid peptide (β-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by anti-amyloid activity.

  提供了一系列新型α-(N-磺酰胺基)乙酰胺化合物的公式(I)，其中R、R1、R2和R3在此定义，它们是β-淀粉样肽（β-AP）产生的抑制剂，并且在治疗阿尔茨海默病和其他受到抗淀粉样蛋白活性影响的疾病中有用。
• Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitors
  作者：Mark J. Wall、Jinsheng Chen、Sanath Meegalla、Shelley K. Ballentine、Kenneth J. Wilson、Renee L. DesJarlais、Carsten Schubert、Margery A. Chaikin、Carl Crysler、Ioanna P. Petrounia、Robert R. Donatelli、Edward J. Yurkow、Lisa Boczon、Marie Mazzulla、Mark R. Player、Raymond J. Patch、Carl L. Manthey、Christopher Molloy、Bruce Tomczuk、Carl R. Illig

  DOI：10.1016/j.bmcl.2008.01.088

  日期：2008.3

  A series of 3,4,6-substituted 2-quinolones has been synthesized and evaluated as inhibitors of the kinase domain of macrophage colony-stimulating factor-1 receptor (FMS). The fully optimized compound, 4-(4-ethyl-phenyl)-3-(2-methyl-3H-imidazol-4yl)-2-quinolone-6-carbonitrile 21b, has an IC50 of 2.5 nM in an in vitro assay and 5.0 nM in a bone marrow-derived macrophage cellular assay. Inhibition of FMS signaling in vivo was also demonstrated in a mouse pharmacodynamic model. (c) 2008 Elsevier Ltd. All rights reserved.